> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viatris Starts $36.50-A-Share Cash Tender Offer For Pacira, A Few Cents Above Its Last Close
- URL: https://www.bullished.co/viatris-starts-36-50-a-share-cash-tender-offer-for-pacira-a-few-cents-above-its-last-close-68747ece/
- Published: 2026-10-30T12:06:09.000Z
- Updated: 2026-11-05T19:29:22.000Z
- Description: The offer has no financing condition and follows an October 8 merger agreement, with Pacira shares closing Thursday at $36.39.
- Author: Matteo Parrino
- Tags: Deals, PCRX, Industry: Healthcare

Viatris, through its subsidiary Peach Purchaser Sub, launched a cash tender offer on Friday for every outstanding share of [Pacira BioSciences](https://www.bullished.co/tag/pcrx/) at [$36.50 a share](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126041224/ny20084254x1%5Fsctot.htm?ref=bullished.co), according to a Schedule TO filed with the SEC. The price sits slightly above the $36.39 at which Pacira shares closed Thursday.

## Terms of the offer

The [$36.50 is payable in cash](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126041224/ny20084254x1%5Fsctot.htm?ref=bullished.co), net of applicable withholding taxes and without interest. The offer is not subject to a financing condition, the filing states, and it follows a merger agreement among Viatris, the purchaser and Pacira dated October 8.

Pacira's market value stood at about $1.5 billion at the time of the original report.

## What Viatris is buying

Pacira, based in Brisbane, California, develops and sells non-opioid pain treatments. Its three products are Exparel, a long-acting local anesthetic injection for postsurgical pain; Zilretta, an extended-release steroid injection for osteoarthritis knee pain; and iovera, a handheld device that uses cold on a targeted nerve to relieve pain without drugs.

In 2025, Exparel sales were $575.1 million, or 79% of total revenues. Zilretta brought in $116.6 million and iovera $24.2 million. Pacira is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis.

## The share count behind the bid

Pacira told Viatris that 39,957,678 shares were outstanding as of October 23, excluding 9,018,591 held in treasury.

Other shares could be added to that count: 5,870,185 under outstanding options, 4,463,236 tied to restricted stock units, and 9,628,260 reserved for conversion of Pacira's 2.125% convertible senior notes due 2029\. The filing also counts performance share units covering 198,257 shares at target and 495,641 at maximum.

Pacira is expected to [report third-quarter results on November 5](https://finance.yahoo.com/markets/stocks/articles/pacira-biosciences-pcrx-reports-next-130031844.html?.tsrc=rss&ref=bullished.co), according to a Yahoo Finance report.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SC TO-T — Viatris Inc re: Pacira BioSciences, Inc. (PCRX)](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126041224/ny20084254x1%5Fsctot.htm?ref=bullished.co) — SEC EDGAR
- [Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth](https://finance.yahoo.com/markets/stocks/articles/pacira-biosciences-pcrx-reports-next-130031844.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on Pacira BioSciences

- [Pacira Board Urges Holders To Take Viatris's $36.50 Cash, Up From $31.00 Opening Bid](https://www.bullished.co/pacira-board-urges-holders-to-take-viatriss-36-50-cash-up-from-31-00-opening-bid-43664943/)
- [Doma Perpetual Sold 2,936,794 Pacira Shares And Now Reports Owning None](https://www.bullished.co/doma-perpetual-sold-2-936-794-pacira-shares-and-now-reports-owning-none-28754ee2/)
- [Viatris Agrees To Buy Pacira For $36.50 A Share In Cash, A $1.65 Billion Deal With A $62.0 Million Break Fee](https://www.bullished.co/viatris-agrees-to-buy-pacira-for-36-50-a-share-in-cash-a-1-65-billion-deal-with-a-62-0-14d71d09/)

[All Pacira BioSciences (PCRX) coverage →](https://www.bullished.co/tag/pcrx/)